Bryostatin-1, fenretinide and 1α, 25 (OH) 2D 3 induce growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6)

Avicenna Journal of Medical Biotechnology

Volumn 3, Issue 4, 2011, Pages 177-193

  Ardekani, Ali M ^a   Fard, Shahrzad Soleymani ^a   Jeddi Tehrani, Mahmood ^a   Ghahremanzade, Ramin ^a  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Acute lymphoblastic leukemia; Apoptosis; Cell differentiation; Flow cytometry

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CALCITRIOL; CASPASE 3; CD19 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; FENRETINIDE; STAUROSPORINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; LEUKEMIA CELL LINE; T LYMPHOCYTE;

EID: 84555205601     PISSN: 20082835     EISSN: 20084625     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Estey E. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14(3):476-479.
2. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006;6(2):117-129.
3. Miller WH, Waxman S. Differentiation induction as a treatment for hematologic malignancies. Onco-gene 2002;21(21):3496-3506.
4. Greenberg ER, Sporn MB. Antioxidant vitamins, cancer, and cardiovascular disease. N Engl J Med 1996;334(18):1189-1190.
5. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15(5):867-910.
6. Smith MA, Anderson B. Where to next with retin-oids for cancer therapy? Clin Cancer Res 2001;7 (10):2955-2957.
7. Adamson PC, Widemann BC, Reaman GH, Seibel NL, Murphy RF, Gillespie AF, et al. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint pediatric oncology branch, national cancer institute, and children's cancer group study. Clin Cancer Res 2001;7(10):3034-3039.
8. Formeilli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11(10):2036-2042.
9. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N(4-hydroxyphenyl) retinamide-in-duced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997;89(16):1191-1198.
10. Maurer BJ, Metelitsa LS, Seeger R, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxy-phenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91(13):1138-1146.
11. Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP. Fenretinide activates caspases and induced apoptosis in gliomas. Clin Cancer Res 1999;5(8):2230-2235.
12. James SY, Williams MA, Kelsey SM, Newland AC, Colston KW. The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem Pharmacol 1997;54(5):625-634.
13. Jung CW, Kim ES, Seol JG, Park WH, Lee SJ, Kim BK, et al. Antiproliferative effect of a vitamin D analog, EB1089, on HL 60 cells by the induction of TGF-b receptor. Leuk Res 1999;23(12):1105-1112.
14. James SY, Williams MA, Colston KW. Leukemia cell differentiation: cellular and molecular interact-tions of retinoids and vitamin D. Gen Pharmacol 1999;32(1):143-154.
15. Yoon JS, Kim JY, Park HK, Kim ES, Ahn KS, Yoon SS, et al. Antileukemic effects of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypocalcaemia. Int J Oncol 2008;32(2):387-396.
16. Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, et al. Growth suppression of ovarian cancer xeno-grafts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 2005;11(1): 323-328.
17. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006;12(19):5895-5901.
18. Mellibovsky L, Diez A, Perez-Vila E, Serrano S, Nacher M, Aubia J. Vitamin D treatment in myelo-dysplastic syndromes. Br J Haematol 1998;100(3): 516-520.
19. Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008;29(6):433-452.
20. Nakagawa K, Kawaura A, Kato S, Takeda E, Oka-no T. 1 α, 25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Car-cinogenesis 2005;26(2):429-440.
21. Sunn KL, Cock TA, Crofts LA, Eisman JA, Gardiner EM. Novel N-terminal variant of human VDR. Mol Endocrinol 2001;15(9):1599-1609.
22. Tagami T, Lutz WH, Kumar R, Jameson JL. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 1998;253(2):358-363.
23. Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, et al. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 2006;12(7 Pt 1):2004-2013.
24. Yan W, Chen W, Liu Z, Huang L. Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Cytokine 2010;52(3):238-244.
25. Clamp A, Jayson GC. The clinical development of the bryostatins. Anticancer Drugs 2002;13(7):673-683.
26. Wang S, Guo C-Y, Castillo A, Dent P, Grant S. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Bio-chem Pharmacol 1998;56(5):635-644.
27. Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphory-lation of cyclin-dependent kinase 2. Cancer Res 1995;55(17):3716-3720.
28. Roberts JD, Smith MR, Feldman EJ, Cragg L, Mil-lenson MM, Roboz GJ. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymph-ocytic leukemia and indolent (non-Hodgkin's) lym-phoma. Clin Cancer Res 2006;12 (19):5809-5816.
29. Faderl S, Lotan R, Kantarjian HP, Harris D, Van Q, Estrov Z. N-(4 Hydroxylphenyl)retinamide (fen-retinide, 4-HPR), a retinoid compound with antileu-kemic and proapoptotic activity in acute lympho-blastic leukemia (ALL). Leuk Res 2003;27(3):259-266.
30. Matsui W, Smith BD, Vala M, Beal N, Huff CA, Diehl LF et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. Br J Haematol 2005;128(6):853-862.
31. Matsui WH, Gladstone DE, Vala MS, Barber JP, Brodsky RA, Smith BD et al. The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth Differ 2002;13(6):275-283.
32. Das A, Banik NL, Ray SK. Retinoids induced astro-cytic differentiation with down regulation of telo-merase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 2008;87(1):9-22.
33. Wagner KD, Wagner N, Sukhatme VP, Scholz H. Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells. J Am Soc Nephrol 2001;12(6):1188-1196.
34. Soleymani S, Jeddi-Tehrani M, Akhondi MM, Hashemi M, Ardekani A. Flow cytometric analysis of 4-HPR-induced apoptosis and cell cycle arrest in acute myelocytic leukemia cell line (NB-4). Avi-cenna J Med Biotech 2010;2(1):53-61.
35. Wagner N, Wagner KD, Schley G, Badiali L, The-res H, Scholz H. 1,25-dihydroxyvitamin D-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res 2003;77(1):1-9.
36. Bastie JN, Balitrand N, Guillemot I, Chomienne C, Delva L. Cooperative action of 1α,25-dihydroxyvit-amin D and retinoic acid in NB4 acute promyelo-cytic leukemia cell differentiation is transcrip-tionally controlled. Exp Cell Res 2005;310(2):319-330.
37. Taimi M, Chateau MT, Cabane S, Marti J. Syner-gistic effect of retinoic acid and 1,25-dihydroxyvit-amin D3 on the differentiation of the human mono-cytic cell line U937. Leuk Res 1991;15(12):1145-1152.
38. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001;90(2-3):105-156.
39. Hotfilder M, Rottgers S, Rosemann A, Jurgens H, Harbott J, Vormoor J. Immature CD34+CD19 progenitor/stem cells in TEL/ AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. Blood 2002;100(2):640-646.
40. Castor A, Nilsson L, Astrand-Grundstrom I, Buit-enhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005;11 (6):630-637.
41. Hotfilder M, Rottgers S, Rosemann A, Schrauder A, Schrappe M, Pieters R, et al. Leukemic stem cells in childhood high-risk ALL/ t(9;22) and t (4;11) are present in primitive lymphoid-restricted CD34+CD19 cells. Cancer Res 2005;65(4):1442-1449.
42. Sato S, Miller AS, Howard MC, Tedder TF. Regulation of B lymphocyte development and activation by the CD19/CD21/ CD81/Leu 13 complex requires the cytoplasmic domain of CD19. J Immunol 1997;159(7):3278-3287.
43. Fujimoto M, Poe JC, Hasegawa M, Tedder TF. CD19 regulates intrinsic B lymphocyte signal trans-duction and activation through a novel mechanism of processive amplification. Immunol Res 2000;22 (2-3):281-298.
44. Donis-Hernandez FR, Parkhouse RM, Santos-Ar-gumedo L. Ontogeny, distribution and function of CD38-expressing B lymphocytes in mice. Eur J Immunol 2001;31(4):1261-1267.
45. Springer LN, Stewart BW. N-(4-Hydroxyphenyl) retinamide-induced death in human lymphoblastoid cells: 50 kb DNA breakage as a means of distinguishing apoptosis from necrosis. Cancer Lett 1998;128(2):189-196.
46. Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, et al. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med 2009;47(5):536-547.
47. Clark CS, Konyer JE, Meckling KA. 1α,25-di-hydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocy tic leukemia cells by modulating cell cycle progression. Exp Cell Res 2004;294(1):301-311.
48. Steube KG, Grunicke D, Ouentmeier H, Drexler HG. Different effects of the two protein kinase C activator bryostatin-1 and TPA on growth and differentiation of human monocytic leukemia cell lines. Leuk Res 1993;17(10):897-901.
49. Chelliah J, Freemerman AJ, Wu-Pang S, Jawis WD, Grant S. Potentiation of ara-C-induced apo-ptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc. Biochem Pharmacol 1997;54(5):563-573.
50. Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke P, May WS. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 1990;75(6):1319-1323.
51. Liu M, Lee MH, Cohen M, Bommakanti M, Freed-man LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10(2):142-153.
52. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl) retinamide increases cer-amide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002;16(5):902-910.
53. Zhang X, Zhang R, Zhao H, Cai H, Gush K, Kerr R, et al. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 1996;56(4):802-808.
54. Kortmansky J, Schwartz G. Bryostatin-1: A novel PKC inhibitor in clinical development. Cancer Invest 2003;21(6):924-936.
55. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Ge-wirtz DA, Pettit GR, et al. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-(beta-D- arabinofuranosyl)cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 1994;47(5): 839-852.
56. Grant S, Turner AJ, Freemerman AJ, Wang Z, Kramer L, Jarvis WD. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. Exp Cell Res 1996;228(1): 65-75.
57. Vrana JA, Saunders AM, Chellappan SP, Grant S. Divergent effects of bryostatin 1 and phorbol myri-state acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation 1998;63(1):33-42.
58. Wall NR, Mohammad RM, Nabha SM, Pettit GR, Al-Katib AM. Modulation of cIAP-1 by novel anti-tubulin agents when combined with bryostatin 1 result in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh. Bio-chem Biophys Res Commun 1999;266(1):76-80.
59. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001;90(2-3):105-156.
60. Studzinski GP, Harrison LE. Differentiation-related changes in the cell cycle traverse. Int Rev Cytol 1999;189:1-58.
61. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apopto-sis 2001;6(5):377-388.
62. Rao AS, Freemerman AJ, Jarvis WD, Chelliah J, Bear HD, Mikkelsen R, et al. Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apo-ptosis in human myeloid leukemia cells. Leukemia 1996;10(7): 1150-1158.
63. Bastie JN, Balitrand N, Guidez F, Guillemot I, Lar-ghero J, Calabresse C, et al. 1α,25-dihydroxyvit-amin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol Endocrinol 2004;18(11):2685-2699.
64. Janardhanan R, Butler JT, Banik NL, Ray SK. N-(4-Hydroxyphenyl) retinamide potentiated pacli-taxel for cell cycle arrest and apoptosis in glioblast-oma C6 and RG2 cells. Brain Res 2009;1268:142-153.
65. Reddy CD, Guttapalli A, Adamson PC, Vemuri MC, O'Rourke D, Sutton LN, et al. Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett 2006;231(2):262-269.
66. Janardhanan R, Banik NL, Ray SK. N-(4-Hydroxy-phenyl) retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-c sensitivity for apoptosis in human glio-blastoma cells. Cancer Lett 2008;261(1):26-36.
67. Wang S, Wang Z, Boise LH, Dent P, Grant S. Bryo-statin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-x. Leukemia 1999;13(10):1564-1573.
68. Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B, et al. Bryostatin 1 induced apoptosis and augments inhibitory effects of Vincristine in human diffuse large cell lymphoma. Leuk Res 1995;19(9):667-673.
69. Artaza JN, Sirad F, Ferrini MG, Norris KC. 1α,25 (OH)2vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J Steroid Biochem Mol Biol 2010;119(1-2):73-83.
70. Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, et al. Combination of a potent 20-epi-vit-amin D3 analogue (KH1060) with 9-cis retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996;56(15):3570-3576.
71. James SY, Turner A, Colston KW. Induction of apoptosis in human leukemia cells is differentially regulated by vitamin D derivatives and retinoids. Hematology 1997;2:289-301.
72. Rajapakse R, Mousli M, Pfaff AW, Uring-Lambert B, Marcellin L, Bronner C, et al. 1α,25-Dihydroxy-vitamin D3 induces splenocyte apoptosis and enhances BALB/c mice sensitivity to toxoplasmosis. J Steroid Biochem Mol Biol 2005;96(2):179-185.
73. Flynn G, Chung I, Yu WD, Romano M, Modzelew-ski RA, Johnson CS, et al. Calcitriol (1,25-dihydro-xycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 2006;70(6):447-457.
74. Hail Jr. N, Kim HJ, Lotan R. Mechanisms of fen-retinide-induced apoptosis. Apoptosis 2006;11(10): 1677-1694.
75. Sun SY, Yue P, Kelloff GJ, Steele VE, Lippman SM, Hong WK, et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl) retinamide in inhibiting growth and inducing apo-ptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Prev 2001;10 (6):595-601.
76. Holmes WF, Soprano DR, Soprano KJ. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J Cell Biochem 2003;89(2):262-278.
77. Boya P, Morales MC, Gonzalez-Polo RA, Andre-aux K, Gourdier I, Perfettini JL, et al. The chemo-preventive agent N-(4-hydroxyphenyl) retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene 2003;22(40):6220-6230.
78. da Costa Alfonso ZZ, de Souza MA, de Castro S, Neumann J, Nardi NB. Monoclonal antibodies detecting differentiation antigens on human leukocytes. Immunol Lett 2003 3;86(1):53-55.
79. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD, Matsui W, et al. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia 2007;21(9):1915-1920.
80. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004;104(9):2919-2925.
81. Stoeckler JD, Stoeckler HA, Kouttab N, Maizel AL. 1alpha, 25Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. J Immunol 1996;157(11):4908-4917.
82. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000;243(1-2):59-75.
83. Lewis RE, Cruse JM, Sanders CM, Webb RN, Till-man BF, Beason KL, et al. The immunophenotype of pre-TALL/LBL revisited. Exp Mol Pathol 2006; 81(2):162-165.
84. Popov AM, Verzhbitskaia TIu, Tsaur GA, Shori-kov EV, Savel'ev LI, Tsvirenko SV, et al. Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia. Klin Lab Diagn 2010;(8):36-41.
85. Babusikova O, Stevulova L, Fajtova M. Immuno-phenotyping parameters as prognostic factors in T-acute leukemia patients. Neoplasma 2009;56(6): 508-513.
86. al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh. J Immunother Emphasis Tumor Immunol 1993;14(1):33-42.
87. Wall NR, Mohammad RM, Al-Katib AM. Mito-gen-activated protein kinase is required for bryo-statin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh. Cell Growth Differ 2001;12(12):641-647.